In this cohort study of patients with type 2 diabetes, the CV benefits associated with GLP-1 RAs were BMI-dependent, with significant reductions in CV death and heart failure hospitalization observed only in patients with BMI 25 or greater. Here, GLP1R is linked to heart failure.